Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000932471-25-000267·Travere Therapeutics, Inc.
Schedule 13G ownership disclosure
TRAVERE THERAPEUTICS INC
Common Stock · CUSIP: 89422G107
Event date: 2024-12-31
- Filing-level shares
- 6,742,165
- Percent of class
- 7.75%
- The Vanguard Group
Shares: 6,742,165 · Class: 7.75%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-000267
- Form type
- SCHEDULE 13G/A
- Filer
- Travere Therapeutics, Inc.
- CIK
- CIK 1438533
- Filed
- Jan 31, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership